No Data
No Data
Here's Why Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Has A Meaningful Debt Burden
Pharmaceutical stocks have become a transitional theme at present, and the performance line may be further valued by the market.
Track the entire lifecycle of the main sector.
Shanghai Fosun Pharmaceutical (Group) Subsidiary's Cancer Drug's NDA Accepted by NMPA
Shanghai Fosun Pharma's New Cancer Drug Application Accepted
FOSUN PHARMA (600196.SH): The registration application for the injectable Raltitrexed Pharmaceutical has been accepted.
FOSUN PHARMA (600196.SH) announced that its controlling subsidiary, Gismay (Wuhan) Pharmaceutical Co., Ltd. ...
On December 30, FOSUN PHARMA (02196.HK) spent 4.94 million Hong Kong dollars to repurchase 0.35 million shares.
Gelonghui reported on December 30 that FOSUN PHARMA (02196.HK) announced that on December 30, it spent 4.94 million Hong Kong dollars to repurchase 0.35 million shares.
No Data